{
    "clinical_study": {
        "@rank": "28435", 
        "arm_group": [
            {
                "arm_group_label": "BI 655064 dose group 1", 
                "arm_group_type": "Experimental", 
                "description": "subject to receive BI 655064 dose group 1 single dose"
            }, 
            {
                "arm_group_label": "Placebo to BI 655064 dose group 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "subject to receive placebo"
            }, 
            {
                "arm_group_label": "BI 655064 dose group 2", 
                "arm_group_type": "Experimental", 
                "description": "subject to receive BI 655064 dose group 2 single dose"
            }, 
            {
                "arm_group_label": "Placebo to BI 655064 dose group 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "subject to receive a placebo"
            }, 
            {
                "arm_group_label": "BI 655064 dose group 4", 
                "arm_group_type": "Experimental", 
                "description": "Subject to receive BI 655064 dose group 4 single dose"
            }, 
            {
                "arm_group_label": "Placebo to BI 655064 dose group 4", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subject to receive placebo"
            }, 
            {
                "arm_group_label": "BI 655064 dose group 3", 
                "arm_group_type": "Experimental", 
                "description": "Subject to receive BI 655064 dose group 3 single dose"
            }, 
            {
                "arm_group_label": "Placebo to BI 655064 dose group 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subject to receive placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 655064 after single rising\n      doses in healthy Asian male volunteers."
        }, 
        "brief_title": "Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy males based upon a complete medical history, including the physical\n             examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests\n\n          -  Chinese ethnicity, Japanese ethnicity according to the following criteria. Japanese:\n             born in Japan, have lived outside of Japan <10 years, and have parents and\n             grandparents who were all born in Japan. Chinese: ethnic Chinese, born in China or\n             ethnic Chinese born outside of China, and a descendent of 4 ethnic Chinese\n             grandparents who were all born in China\n\n          -  Age within the range of 20 to 45 years inclusive\n\n          -  Body mass index within the range of 18.5 and 25 kg/m2 inclusive\n\n          -  Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and the local legislation.\n\n        Exclusion criteria:\n\n          -  Any finding of the medical examination (including BP, PR and ECG) deviating from\n             normal and of clinical relevance\n\n          -  Any disease or clinically relevant abnormality in laboratory parameters which,\n             according to the investigator, might compromise the safety of the subject or\n             interfere with the subjects participation in the trial or compromise the trial\n             objectives\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or\n             neurological disorders\n\n          -  History of relevant orthostatic hypotension, fainting spells or blackouts.\n\n          -  Chronic or relevant acute infections"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917916", 
            "org_study_id": "1293.8"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo to BI 655064 dose group 4", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655064 dose group 2", 
                "intervention_name": "BI 655064", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655064 dose group 3", 
                "intervention_name": "BI 655064", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655064 dose group 4", 
                "intervention_name": "BI 655064", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to BI 655064 dose group 3", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655064 dose group 1", 
                "intervention_name": "BI 655064", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to BI 655064 dose group 1", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to BI 655064 dose group 2", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sumida-ku,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1293.8.8101 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1293.8.8201 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "8", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebocontrolled Within Dose Groups, Clinical Phase I Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "South Korea: Ministry of Food and Drug Safety (MFDS)"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with drug-related adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 91 days post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917916"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "up to 70 days post dose"
            }, 
            {
                "measure": "AUC0-infinity", 
                "safety_issue": "No", 
                "time_frame": "up to 70 days post dose"
            }, 
            {
                "measure": "AUC0-tz", 
                "safety_issue": "No", 
                "time_frame": "up to 70 days post dose"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}